Production & Manufacturing

For years, global healthcare systems have been facing the triple threat of rising incidences of long-term conditions (LTC), aging populations and dwindling resources. At the same time, we have seen worldwide calls for affordable medicines – from the Jan...

The global oral solid dosage (OSD) contract manufacturing market is anticipated to reach $54.7 billion in value by 2030, exhibiting a compound annual growth rate (CAGR) of 6%, according to a market analysis. As per data, oral solids are the...

The global pharmaceutical contract manufacturing market is anticipated to reach $130.2 billion by 2026 as a result of increasing demand for pharmaceuticals, particularly in developing economies. In 2020, the market was estimated to be worth $100 billion. Market research indicates...

A recent survey found that 86.9% of biopharmaceutical businesses outsource at least a portion of their operations, which has contributed to the $14 billion market for biopharmaceutical contract manufacturing. Over the next ten years, the investigators predict a very bright...

Bribes and rebate arrangements involving drugmakers and pharma middlemen are all being investigated by US regulators, with a particular focus on rising insulin prices. The Federal Trade Commission (FTC) announced recently that it would step up enforcement against practises...

COVID-19's propensity to fuel domestic drug production hasn't waned two years into the pandemic. Take, for example, Pfizer's new $120 million investment. The company announced on June 6 that it will use the funds to expand manufacturing of its oral...

RCPE and InSilicoTrials have agreed to an exclusive partnership to commercialize the XPS simulation software. Specifically developed for pharmaceutical applications, XPS allows companies to assess their process configurations in unprecedented detail and explore the decision space without time- and...